Tofacitinib Completed Phase 4 Trials for Axial Spondyloarthritis (AxSpA) Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT06310057Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study